Antibody‐based strategies for the detection of Luspatercept (ACE‐536) in human serum

Skip to Navigation

EarlyView Article

  • Published: Nov 9, 2017
  • Author: Christian Reichel, Günter Gmeiner, Mario Thevis
  • Journal: Drug Testing and Analysis

Luspatercept (ACE‐536, ACVR2B‐Fc), a fusion protein consisting of the extracellular domain of ActRIIB receptor and the Fc‐part of human immunoglobulin G1 (IgG1), is currently under clinical development (Phase III). It stimulates the formation of red blood cells and hence may be misused by athletes for doping purposes in the future. Several antibody‐based strategies for the detection of Luspatercept and other ACVR2B‐Fc fusion proteins in human serum were evaluated (ELISA; IEF‐, SDS‐, and SAR‐PAGE followed by Western blotting; immunoprecipitation). Two methods led to useful results: a commercial “soluble” ACTR‐IIB ELISA, which also detected Luspatercept and other ACVR2B‐Fc's, but showed no cross‐reactivity with Sotatercept/ACVR2A‐Fc's. The ELISA might be applied as fast screening tool (100 μL serum; limit of detection (LOD) ca 15.6 ng/mL). The second method uses a polyclonal ACVR2B‐antibody for immunoprecipitation followed by SAR‐PAGE and Western blotting with a monoclonal detection antibody (50 μL serum; LOD ca 1.0 ng/mL). It can be used for initial as well as for confirmatory testing. Due to the high doses (mg/kg) and long serum half‐life of Luspatercept, both strategies may be useful in anti‐doping control in the future. Copyright © 2017 John Wiley & Sons, Ltd.

Social Links

Share This Links

Bookmark and Share


Suppliers Selection
Societies Selection

Banner Ad

Click here to see
all job opportunities

Most Viewed

Copyright Information

Interested in spectroscopy? Visit our sister site

Copyright © 2017 John Wiley & Sons, Inc. All Rights Reserved